NCT07179328
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 1 of 3 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants in this single-arm study will undergo repeated sessions (up to 6 cycles spaced 4-6 weeks apart) of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) during the maintenance phase of standard-of-care temozolomide (TMZ) chemotherapy. At the time of each FUS session, participants will receive their prescribed standard of care TMZ dose, as well as an intravenous injection of DEFINITY® ultrasound contrast agent that enables targeted BBB opening. Each session will be guided by MRI, and imaging will be used to assess the extent of BBB disruption. Clinical and safety assessments, blood sampling for biomarker analysis, and follow-up imaging will be conducted throughout the study period.
Devices: Focused Ultrasound Next Generation Dome Helmet
Drugs: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Sites
1 site in 1 country
- Sunnybrook Health Sciences CentreToronto, Ontario, Canada